Ronald I. Meltzer
Direttore/Membro del Consiglio presso Sequella, Inc.
Profilo
Ronald I.
Meltzer is currently a Director at Sequella, Inc. and a Member-Washington Leadership Board at State University of New York at Buffalo Law School.
He formerly worked as a Principal at American University and as a Professor at State University of New York at Buffalo.
He holds a doctorate degree from The Trustees of Columbia University in The City of New York, a graduate degree from New York University, and an undergraduate degree from The Ohio University.
Posizioni attive di Ronald I. Meltzer
Società | Posizione | Inizio |
---|---|---|
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | Direttore/Membro del Consiglio | - |
State University of New York at Buffalo Law School | Corporate Officer/Principal | 20/07/2011 |
Precedenti posizioni note di Ronald I. Meltzer
Società | Posizione | Fine |
---|---|---|
American University | Corporate Officer/Principal | - |
State University of New York at Buffalo | Corporate Officer/Principal | - |
Formazione di Ronald I. Meltzer
New York University | Graduate Degree |
The Trustees of Columbia University in The City of New York | Doctorate Degree |
The Ohio University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | Health Technology |
- Borsa valori
- Insiders
- Ronald I. Meltzer